Fig. 7.
RGFP-966 reduces Aβ in the brain and plasma of 3xTg-AD mice. RGFP-966 significantly decreased Aβ1–42 in (A) the PBMCs and in (B) the brain of 3xTg-AD mice in: the prefrontal cortex (PFC) at 3 kg/kg RGFP-966 and 10 mg/kg; in the entorhinal cortex (ERC) at 10 mg/kg; in the hippocampus (HIP) at 10 mg/kg (C). RGFP-966 increased NEP expression in the PBMCs in a dose-dependent manner with no effect of NEP expression in the brain (D). For all tests, one-way ANOVA with Dunnett’s multiple-comparisons test was used. The graphs represent mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.001; n = 5–6.